Contrast Agents and Oral Factor Xa Inhibitor
Conditions
Brief summary
The aim of this study is to evaluate the effect of iohexol as a contrast agent on the anticoagulant activity of oral factor Xa inhibitors.
Detailed description
The study included 65 people who underwent contrast computerized tomography (CT). The study patients were divided into 4 groups. Patients in group 1 were using rivaroxaban (20 patients), patients in group 2 were using apixaban (20 patients), patients in group 3 were using edoxaban (20 patients), and group 4 was the control group (5 volunteers). Iohexol (60 ml) was used as a contrast agent. Two tubes were used to collect 2 ml of blood from the patients at 4 hours after the drug dose (rivaroxaban, apixaban, or edoxaban) and 1 hour after the contrast CT (CT was performed 3 hours after the drug was taken). In the control group, at any time and 1 hour after contrast CT, 2 tubes of 2 ml of blood were collected. The anticoagulant properties of rivaroxaban, apixaban, and edoxaban were evaluated using anti-factor Xa levels.
Interventions
Anti Factor Xa level
Sponsors
Bursa Postgraduate Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. the use of oral factor Xa inhibitors (patients with nonvalvular AF and CHA2DS2-VASc Score ≥2), 2. age of 21-80 years, 3. no contraindications for anticoagulation use, 4. GFR greater than 30, 5. volunteering to participate in the study, and 6. patients who needed to use contrast agent (iohexol) for CT examination. -
Exclusion criteria
1. coagulopathy, 2. severe hepatic insufficiency, 3. chronic systemic or inflammatory diseases, 4. patients lighter than 60 kg, 5. malignancy, 6. creatinine value above 1.5 mg/dl, and 7. not providing consent to participate in the study -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti Factor Xa level | 14 days |
Countries
Turkey (Türkiye)
Outcome results
None listed